Lilly gene-targeted drug shows potential for use across cancers

A gene-targeted drug sold by Eli Lilly can shrink tumors in a wide range of cancer types, not just the lung and thyroid malignancies in which the DNA mutations it's aimed at are most prevalent, new study results show.

Treatment with the drug, called Retevmo, led to tumor responses in nearly half of 32 participants studied in the trial, who collectively had 12 different types of cancer.